Efficacy and Safety of MA and MAL on reducing body weight and body fat in overweight subjects; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

MSC0 个研究点目标入组 150 人开始时间: 待定最近更新: 2019年6月17日

试验速览

暂无简介。

•1) Adults 20 years of age or older and 65 years of age or younger
•2) Body mass index (BMI) is greater than 25, less than 32
•3) The person who agrees to participate in this study and wrote the written informed consent

•1) Those with severe cerebrovascular disease, heart disease (angina pectoris, myocardial infarction, heart failure, or arrhythmia requiring treatment) within the past 6 months.
•2) Those taking drugs affecting body weight within the past month (absorption inhibitors and appetite suppressants, health functional foods / supplements related to obesity improvement, psychiatric drugs such as depression, beta-blockers, diuretics, oral contraceptive pills, steroids and female hormones)
•3) Unadjusted hypertension patients (blood pressure of 160/100 mmHg or higher)
•4) Diabetic patients with fasting blood glucose levels greater than 126 mg / dl or with oral hypoglycemic agents or insulin
•5) Thyroid stimulating hormone (TSH) less than 0.1 µU / ml or more than 10 µU / ml or currently taking thyroid hormone
•6) Creatinine is at least twice the normal upper limit of the test facility
•7) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is more than three times the normal upper limit.
•8) Persons with severe gastrointestinal disturbances who are suffering from ingestion of test food
•9) Those who were admitted to the hospital, or have received medication or rehabilitation due to alcohol use
•10) Those who cannot exercise because of musculoskeletal disorders
•11) Those who participated in the commercial obesity program within the last 3 months
•12) Those who participated or planned to participate in other clinical trials within the past one month

发起方